{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-152380","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.101920+00:00","generated_at":"2026-06-01T06:52:56.337631+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"WTX-124 Phase 1/1b shows 3 objective responses (1 CR) in checkpoint-refractory solid tumors","bullets":["3 objective responses out of 35 monotherapy-treated patients: 1 confirmed complete response, 2 partial responses.","All responding patients had 100% target lesion regression; responses durable at recommended dose for expansion (RDE).","RDE selected as 18 mg IV every 2 weeks; three expansion arms opened in RCC, melanoma, cutaneous SCC.","WTX-124 + pembrolizumab combination well-tolerated with enhanced T-cell activation in tumors; no new safety signals.","Company plans to engage regulators on potential monotherapy accelerated approval pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-152380","json":"https://secwatch.observer/filing/0001193125-24-152380.json","markdown":"https://secwatch.observer/filing/0001193125-24-152380.md","text":"https://secwatch.observer/filing/0001193125-24-152380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524152380/0001193125-24-152380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524152380/d800910d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:52:56.337631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}